Anne Altmeyer - 19 May 2026 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Director
Issuer ticker: CRBP
Reported as of: 19 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2026, 17:05:51 UTC
Prior SEC filing: 21 Oct 2025
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer

Key filing fact

Anne Altmeyer filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 21 May 2026.

Key facts

This page summarizes Anne Altmeyer's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 May 2026, 17:05.

Change

Previous filing in this sequence was filed on 21 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001947086 Primary reporting owner

Altmeyer Anne

Relationship: Director
Address: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD
Signature: /s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer
Signature date: 21 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBP transaction

Common Stock, par value $0.0001 per share

Award

Transaction value
Shares: +3,800
Change %: +61%
Price: $0.000000^*
Shares after: 9,991
Date: 19 May 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBP transaction Derivative

Stock options (right to buy)

Award

Transaction value
Shares: +12,300
Change %
Price: $0.000000^*
Shares after: 12,300
Date: 19 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,300
Exercise price: $9.15
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

Footnote F2

This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.

Footnote F3

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.